Amikacin (Amikin)

Amikacin is an approved antibiotic used for treating severe bacterial infections. In the test tube it is active against Mycobacterium avium intracellulare (MAI) organisms and it is being studied in combination with other drugs for treating the condition. It is administered by intramuscular or intravenous injection. Side-effects can include hearing, balance and kidney abnormalities.

Amikacin is also known as amikacin sulphate. It is manufactured by Bristol-Myers Squibb under the trade name Amikin .

A liposomal version of amikacin has been developed by Nexstar Pharmaceuticals under the trade name Mikasome . A study of liposomal amikacin in nine people with non-tuberculous mycobacteria (mostly MAI infection), has been reported. Dosage was 20mg/kg on alternate days for two weeks. Of the nine, one patient discontinued, one developed renal failure, and one an anaphylactic reaction to the treatment. Of the other six, five seroconverted to a negative blood culture and all six responded clinically. Of four patients who remained on maintenance therapy, all relapsed between 0.5 and 5 months after induction. All were successfully re-induced on treatment at 30 or 40mg/kg on alternate days. One other of these four developed kidney failure, which responded to cessation of non-steroidal anti-inflammatory drugs (NSAIDs). No other toxicities were noted.1


  1. Nelson M et al. Liposomal amikacin (LA) for the treatment of non-tuberculous mycobacteria (NTM) in HIV disease. Twelfth World AIDS Conference, Geneva, abstract 22170, 1998

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.